Moving from the Informed Consent to Approved Labeling: Preparing for Risks in Product Marketing & Use

Join Goodwin FDA Regulatory partner, Julie Tibbets, Products Litigation + Counseling partner, and Risk Management & Insurance counsel Brian Mukherjee as they discuss what drug and biologic companies with late-stage product candidates can do to best position their products to mitigate the risks that come with transitioning from clinical trials to marketing and sales.

Our speakers – leaders in life sciences regulatory compliance, product litigation preparedness, risk management, and insurance – will highlight best practices surrounding pharmaceutical promotion, preparing for risks inherent in the marketing and sale of prescription drugs, and the ways in which insurance can help mitigate those risks. The webinar will identify the key takeaways for companies that are nearing FDA approval and are poised to launch their commercial products.